Gene Therapy Market Analysis,Growth, Insights and Future Outlook | Exactitude Consultancy [Yahoo! Finance]
Ultragenyx Pharmaceutical Inc. (NASDAQ: RARE) had its "buy" rating re-affirmed by analysts at HC Wainwright. They now have a $95.00 price target on the stock.
Ultragenyx Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
Ultragenyx Pharmaceutical Inc. (NASDAQ: RARE) had its price target raised by analysts at Wells Fargo & Company from $75.00 to $88.00. They now have an "overweight" rating on the stock.
NHS England Rolls Out Evkeeza® ?(evinacumab) for Eligible Adults and Adolescents Aged 12 Years and Older with Homozygous Familial Hypercholesterolaemia (HoFH) [Yahoo! Finance]